Lisuride in parkinsonism
- 1 April 1981
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 31 (4), 371
- https://doi.org/10.1212/wnl.31.4.371
Abstract
We studied the actions of lisuride, a dopaminergic ergot derivative, in 20 parkinsonian patients. When the dose was increased gradually, most patients tolerated up to 5 mg daily. Clinical assessment and objective, computer-assisted evaluation revealed improvement in akinesia, rigidity and tremor. Adverse reactions were similar to those seen with levodopa and bromocriptine, but somnolence tended to occur more often with lisuride.This publication has 7 references indexed in Scilit:
- Release ofα-Melanocyte-Stimulating Hormone from Dispersed Cells of the Intermediate Lobe of the Rat Pituitary Gland: Involvement of Catecholamines and Adenosine 3′,5′-MonophosphateEndocrinology, 1980
- Dopamine receptors and sleep induction in man.Journal of Neurology, Neurosurgery & Psychiatry, 1979
- Lisuride and LSD: Dopaminergic and serotonergic interactions in the ?serotonin syndrome?Psychopharmacology, 1979
- Multiple receptors for dopamineNature, 1979
- EEG Sleep Study in Parkinsonian Patients under Bromocryptine TreatmentEuropean Neurology, 1978
- BROMOCRIPTINE AND LEVODOPA (WITH OR WITHOUT CARBIDOPA) IN PARKINSONISMThe Lancet, 1976
- Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in miceEuropean Journal of Pharmacology, 1976